Keywords: China, Acute coronary syndrome, Market forecasts, Decison Resources, AstraZeneca, Brilinto, Salofi, Plavix, Eli Lilly, Effient

China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015

Article | 22 November 2011

Print This

The acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million in 2015. According to advisory ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in